Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis

Hirokazu Kanegane, Xi Yang, Meina Zhao, Kazumi Yamato, Masami Inoue, Kazuko Hamamoto, Chie Kobayashi, Ako Hosono, Yoshikiyo Ito, Yozo Nakazawa, Kiminori Terui, Kazuhiro Kogawa, Eiichi Ishii, Ryo Sumazaki, Toshio Miyawaki

研究成果: ジャーナルへの寄稿記事

17 引用 (Scopus)

抄録

Objective: X-linked lymphoproliferative syndrome (XLP) type 1 is a rare immunodeficiency, which is caused by mutations in SH2D1A gene. The prognosis of XLP is very poor, and hematopoietic stem cell transplantation (HSCT) is the only curative therapy. We characterized the clinical features and outcome of Japanese patients with XLP-1. Methods: We used a combination of flow cytometric analysis and genetic analysis to identify XLP-1 and reviewed the patient characteristics and survival with HSCT. Results: We identified 33 patients from 21 families with XLP-1 in Japan. Twenty-one of the patients (65%) who did not undergo a transplant died of the disease and complications. Twelve patients underwent HSCT, and 11 of these (92%) survived. Conclusion: We described the clinical characteristics and outcomes of Japanese patients with XLP-1, and HSCT was the only curative therapy for XLP-1. The rapid and accurate diagnosis of XLP with the combination of flow cytometric assay and genetic analysis is important.

元の言語英語
ページ(範囲)488-493
ページ数6
ジャーナルPediatric Allergy and Immunology
23
発行部数5
DOI
出版物ステータス出版済み - 8 1 2012

Fingerprint

Lymphoproliferative Disorders
Japan
Hematopoietic Stem Cell Transplantation
Transplants
Mutation
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Immunology

これを引用

Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis. / Kanegane, Hirokazu; Yang, Xi; Zhao, Meina; Yamato, Kazumi; Inoue, Masami; Hamamoto, Kazuko; Kobayashi, Chie; Hosono, Ako; Ito, Yoshikiyo; Nakazawa, Yozo; Terui, Kiminori; Kogawa, Kazuhiro; Ishii, Eiichi; Sumazaki, Ryo; Miyawaki, Toshio.

:: Pediatric Allergy and Immunology, 巻 23, 番号 5, 01.08.2012, p. 488-493.

研究成果: ジャーナルへの寄稿記事

Kanegane, H, Yang, X, Zhao, M, Yamato, K, Inoue, M, Hamamoto, K, Kobayashi, C, Hosono, A, Ito, Y, Nakazawa, Y, Terui, K, Kogawa, K, Ishii, E, Sumazaki, R & Miyawaki, T 2012, 'Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis', Pediatric Allergy and Immunology, 巻. 23, 番号 5, pp. 488-493. https://doi.org/10.1111/j.1399-3038.2012.01282.x
Kanegane, Hirokazu ; Yang, Xi ; Zhao, Meina ; Yamato, Kazumi ; Inoue, Masami ; Hamamoto, Kazuko ; Kobayashi, Chie ; Hosono, Ako ; Ito, Yoshikiyo ; Nakazawa, Yozo ; Terui, Kiminori ; Kogawa, Kazuhiro ; Ishii, Eiichi ; Sumazaki, Ryo ; Miyawaki, Toshio. / Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis. :: Pediatric Allergy and Immunology. 2012 ; 巻 23, 番号 5. pp. 488-493.
@article{4ceca63f265c4ac4aef58dcc91b5aea4,
title = "Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis",
abstract = "Objective: X-linked lymphoproliferative syndrome (XLP) type 1 is a rare immunodeficiency, which is caused by mutations in SH2D1A gene. The prognosis of XLP is very poor, and hematopoietic stem cell transplantation (HSCT) is the only curative therapy. We characterized the clinical features and outcome of Japanese patients with XLP-1. Methods: We used a combination of flow cytometric analysis and genetic analysis to identify XLP-1 and reviewed the patient characteristics and survival with HSCT. Results: We identified 33 patients from 21 families with XLP-1 in Japan. Twenty-one of the patients (65{\%}) who did not undergo a transplant died of the disease and complications. Twelve patients underwent HSCT, and 11 of these (92{\%}) survived. Conclusion: We described the clinical characteristics and outcomes of Japanese patients with XLP-1, and HSCT was the only curative therapy for XLP-1. The rapid and accurate diagnosis of XLP with the combination of flow cytometric assay and genetic analysis is important.",
author = "Hirokazu Kanegane and Xi Yang and Meina Zhao and Kazumi Yamato and Masami Inoue and Kazuko Hamamoto and Chie Kobayashi and Ako Hosono and Yoshikiyo Ito and Yozo Nakazawa and Kiminori Terui and Kazuhiro Kogawa and Eiichi Ishii and Ryo Sumazaki and Toshio Miyawaki",
year = "2012",
month = "8",
day = "1",
doi = "10.1111/j.1399-3038.2012.01282.x",
language = "English",
volume = "23",
pages = "488--493",
journal = "Pediatric Allergy and Immunology",
issn = "0905-6157",
publisher = "Blackwell Munksgaard",
number = "5",

}

TY - JOUR

T1 - Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis

AU - Kanegane, Hirokazu

AU - Yang, Xi

AU - Zhao, Meina

AU - Yamato, Kazumi

AU - Inoue, Masami

AU - Hamamoto, Kazuko

AU - Kobayashi, Chie

AU - Hosono, Ako

AU - Ito, Yoshikiyo

AU - Nakazawa, Yozo

AU - Terui, Kiminori

AU - Kogawa, Kazuhiro

AU - Ishii, Eiichi

AU - Sumazaki, Ryo

AU - Miyawaki, Toshio

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Objective: X-linked lymphoproliferative syndrome (XLP) type 1 is a rare immunodeficiency, which is caused by mutations in SH2D1A gene. The prognosis of XLP is very poor, and hematopoietic stem cell transplantation (HSCT) is the only curative therapy. We characterized the clinical features and outcome of Japanese patients with XLP-1. Methods: We used a combination of flow cytometric analysis and genetic analysis to identify XLP-1 and reviewed the patient characteristics and survival with HSCT. Results: We identified 33 patients from 21 families with XLP-1 in Japan. Twenty-one of the patients (65%) who did not undergo a transplant died of the disease and complications. Twelve patients underwent HSCT, and 11 of these (92%) survived. Conclusion: We described the clinical characteristics and outcomes of Japanese patients with XLP-1, and HSCT was the only curative therapy for XLP-1. The rapid and accurate diagnosis of XLP with the combination of flow cytometric assay and genetic analysis is important.

AB - Objective: X-linked lymphoproliferative syndrome (XLP) type 1 is a rare immunodeficiency, which is caused by mutations in SH2D1A gene. The prognosis of XLP is very poor, and hematopoietic stem cell transplantation (HSCT) is the only curative therapy. We characterized the clinical features and outcome of Japanese patients with XLP-1. Methods: We used a combination of flow cytometric analysis and genetic analysis to identify XLP-1 and reviewed the patient characteristics and survival with HSCT. Results: We identified 33 patients from 21 families with XLP-1 in Japan. Twenty-one of the patients (65%) who did not undergo a transplant died of the disease and complications. Twelve patients underwent HSCT, and 11 of these (92%) survived. Conclusion: We described the clinical characteristics and outcomes of Japanese patients with XLP-1, and HSCT was the only curative therapy for XLP-1. The rapid and accurate diagnosis of XLP with the combination of flow cytometric assay and genetic analysis is important.

UR - http://www.scopus.com/inward/record.url?scp=84864130567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864130567&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3038.2012.01282.x

DO - 10.1111/j.1399-3038.2012.01282.x

M3 - Article

C2 - 22433061

AN - SCOPUS:84864130567

VL - 23

SP - 488

EP - 493

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

SN - 0905-6157

IS - 5

ER -